Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05317416




Registration number
NCT05317416
Ethics application status
Date submitted
18/03/2022
Date registered
7/04/2022
Date last updated
27/11/2024

Titles & IDs
Public title
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
Scientific title
A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION
Secondary ID [1] 0 0
2021-006052-14
Secondary ID [2] 0 0
C1071007
Universal Trial Number (UTN)
Trial acronym
MagnetisMM-7
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Multiple Myeloma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Other cancer types

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Elranatamab
Treatment: Drugs - Lenalidomide
Treatment: Drugs - Lenalidomide
Treatment: Drugs - Elranatamab

Experimental: Arm A - Part 1 - Elranatamab

Active comparator: Arm B - Part 1 - Lenalidomide

Active comparator: Arm B - Part 2 - Lenalidomide

Experimental: Arm C - Part 2 - Elranatamab


Treatment: Drugs: Elranatamab
BCMA-CD3 bispecific antibody

Treatment: Drugs: Lenalidomide
Immunomodulatory drug

Treatment: Drugs: Lenalidomide
Immunomodulatory drug

Treatment: Drugs: Elranatamab
BCMA-CD3 bispecific antibody
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression Free Survival
Timepoint [1] 0 0
Assessed for up to approximately 5 years
Secondary outcome [1] 0 0
Overall Survival
Timepoint [1] 0 0
Assessed for up to approximately 5 years
Secondary outcome [2] 0 0
Minimal Residual Disease negativity rate
Timepoint [2] 0 0
12 months after randomization
Secondary outcome [3] 0 0
Sustained MRD negativity rate
Timepoint [3] 0 0
24 months after randomization
Secondary outcome [4] 0 0
Progression Free Survival
Timepoint [4] 0 0
Assessed for up to approximately 5 years
Secondary outcome [5] 0 0
Overall minimal residual disease negativity rate
Timepoint [5] 0 0
Assessed for up to approximately 5 years
Secondary outcome [6] 0 0
Duration of minimal residual disease negativity
Timepoint [6] 0 0
Assessed for up to approximately 5 years
Secondary outcome [7] 0 0
Sustained minimal residual disease negativity rate
Timepoint [7] 0 0
Assessed for up to approximately 5 years
Secondary outcome [8] 0 0
Complete response rate
Timepoint [8] 0 0
Assessed for up to approximately 5 years
Secondary outcome [9] 0 0
Duration of complete response
Timepoint [9] 0 0
Assessed for up to approximately 5 years
Secondary outcome [10] 0 0
Frequency of adverse events
Timepoint [10] 0 0
Up to 90 days after last dose
Secondary outcome [11] 0 0
Frequency of laboratory abnormalities
Timepoint [11] 0 0
Assessed for up to approximately 5 years
Secondary outcome [12] 0 0
Pre-dose concentrations of elranatamab
Timepoint [12] 0 0
Assessed for up to approximately 5 years
Secondary outcome [13] 0 0
Post-dose concentrations of elranatamab
Timepoint [13] 0 0
Assessed for up to approximately 5 years
Secondary outcome [14] 0 0
Incidence and titers of Anti-Drug Antibody and Neutralizing Antibody against elranatamab
Timepoint [14] 0 0
Assessed for up to approximately 5 years
Secondary outcome [15] 0 0
Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30
Timepoint [15] 0 0
Assessed for up to approximately 5 years
Secondary outcome [16] 0 0
Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Myeloma 20
Timepoint [16] 0 0
Assessed for up to approximately 5 years
Secondary outcome [17] 0 0
Progression Free Survival 2
Timepoint [17] 0 0
Assessed for up to approximately 5 years

Eligibility
Key inclusion criteria
* Diagnosis of MM as defined according to IMWG criteria (Rajkumar, 2014) with measurable disease at diagnosis
* Part 1 patients must be MRD positive, Part 2 patients can be MRD negative or MRD positive
* History of induction therapy for newly diagnosed MM, followed by high dose therapy and autologous stem cell transplant. Randomization must occur within 120 days from the stem cell transplant. For participants who receive consolidation therapy after ASCT, randomization must occur within 60 days of consolidation and within 7 months from ASCT.
* Partial Response or better according to IMWG criteria at the time of randomization
* Must have an archival bone marrow aspirate sample(s) to identify the dominant malignant (index) clone by central laboratory NGS test (ClonoSEQ assay) that is used to track MRD status. This sample should preferably be collected before induction treatment (eg, at diagnosis) or before transplant.
* ECOG performance status =1
* Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade = 1
* Not pregnant and willing to use contraception
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Plasma cell leukemia
* Amyloidosis, Waldenström's macroglobulinemia
* POEMS syndrome
* Known active CNS involvement or clinical signs of myelomatous meningeal involvement
* Previous MM maintenance treatment
* Prior treatment with BCMA targeted therapy
* Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ
* Active, uncontrolled bacterial, fungal, or viral infection, including (but not limited to) HBV, HCV, and known HIV or AIDS-related illness
* Previous administration with an investigational drug or vaccine within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
25/03/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/10/2029
Actual
Sample size
Target
760
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [2] 0 0
Shoalhaven District Memorial Hospital - Nowra
Recruitment hospital [3] 0 0
Westmead Hospital - Westmead
Recruitment hospital [4] 0 0
Wollongong Hospital - Wollongong
Recruitment hospital [5] 0 0
Pindara Private Hospital - Benowa
Recruitment hospital [6] 0 0
QScan Radiology Clinics - Clayfield
Recruitment hospital [7] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment hospital [8] 0 0
Epworth Healthcare - East Melbourne
Recruitment hospital [9] 0 0
Precision Haematology - East Melbourne
Recruitment hospital [10] 0 0
St Vincent's Hospital (Melbourne) - Fitzroy
Recruitment hospital [11] 0 0
Slade Pharmacy - Richmond
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2541 - Nowra
Recruitment postcode(s) [3] 0 0
2145 - Westmead
Recruitment postcode(s) [4] 0 0
2500 - Wollongong
Recruitment postcode(s) [5] 0 0
4217 - Benowa
Recruitment postcode(s) [6] 0 0
4011 - Clayfield
Recruitment postcode(s) [7] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [8] 0 0
3002 - East Melbourne
Recruitment postcode(s) [9] 0 0
3065 - Fitzroy
Recruitment postcode(s) [10] 0 0
3121 - Richmond
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
District of Columbia
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Kansas
Country [7] 0 0
United States of America
State/province [7] 0 0
Michigan
Country [8] 0 0
United States of America
State/province [8] 0 0
Mississippi
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
Ohio
Country [11] 0 0
United States of America
State/province [11] 0 0
Texas
Country [12] 0 0
Austria
State/province [12] 0 0
Wien
Country [13] 0 0
Austria
State/province [13] 0 0
Vienna
Country [14] 0 0
Belgium
State/province [14] 0 0
Bruxelles-capitale, Région DE
Country [15] 0 0
Belgium
State/province [15] 0 0
Hainaut
Country [16] 0 0
Belgium
State/province [16] 0 0
Namur
Country [17] 0 0
Belgium
State/province [17] 0 0
Antwerpen
Country [18] 0 0
Belgium
State/province [18] 0 0
Brussel
Country [19] 0 0
Brazil
State/province [19] 0 0
Bahia
Country [20] 0 0
Brazil
State/province [20] 0 0
RIO Grande DO SUL
Country [21] 0 0
Brazil
State/province [21] 0 0
SÃO Paulo
Country [22] 0 0
Brazil
State/province [22] 0 0
Jaú
Country [23] 0 0
Brazil
State/province [23] 0 0
Rio de Janeiro
Country [24] 0 0
Brazil
State/province [24] 0 0
São Paulo
Country [25] 0 0
Canada
State/province [25] 0 0
Alberta
Country [26] 0 0
Canada
State/province [26] 0 0
New Brunswick
Country [27] 0 0
Canada
State/province [27] 0 0
Ontario
Country [28] 0 0
Canada
State/province [28] 0 0
Quebec
Country [29] 0 0
China
State/province [29] 0 0
Guangdong
Country [30] 0 0
China
State/province [30] 0 0
Hubei
Country [31] 0 0
China
State/province [31] 0 0
Tianjin
Country [32] 0 0
China
State/province [32] 0 0
Zhejiang
Country [33] 0 0
China
State/province [33] 0 0
Shanghai
Country [34] 0 0
Czechia
State/province [34] 0 0
Brno-mesto
Country [35] 0 0
Czechia
State/province [35] 0 0
Hradec Králové
Country [36] 0 0
Czechia
State/province [36] 0 0
Moravskoslezský KRAJ
Country [37] 0 0
Czechia
State/province [37] 0 0
Olomouc
Country [38] 0 0
Czechia
State/province [38] 0 0
Praha 2
Country [39] 0 0
Finland
State/province [39] 0 0
Pohjois-pohjanmaa
Country [40] 0 0
Finland
State/province [40] 0 0
Uusimaa
Country [41] 0 0
Finland
State/province [41] 0 0
Varsinais-suomi
Country [42] 0 0
France
State/province [42] 0 0
Haute-garonne
Country [43] 0 0
France
State/province [43] 0 0
Orne
Country [44] 0 0
France
State/province [44] 0 0
Val-de-marne
Country [45] 0 0
France
State/province [45] 0 0
Vienne
Country [46] 0 0
France
State/province [46] 0 0
La Tronche
Country [47] 0 0
France
State/province [47] 0 0
Lille
Country [48] 0 0
France
State/province [48] 0 0
Paris Cedex 12
Country [49] 0 0
France
State/province [49] 0 0
Pierre Benite
Country [50] 0 0
France
State/province [50] 0 0
Tours
Country [51] 0 0
Germany
State/province [51] 0 0
Bayern
Country [52] 0 0
Germany
State/province [52] 0 0
Nordrhein-westfalen
Country [53] 0 0
Germany
State/province [53] 0 0
Rheinland-pfalz
Country [54] 0 0
Germany
State/province [54] 0 0
Sachsen
Country [55] 0 0
Germany
State/province [55] 0 0
Schleswig-holstein
Country [56] 0 0
Germany
State/province [56] 0 0
Berlin
Country [57] 0 0
Germany
State/province [57] 0 0
Chemnitz
Country [58] 0 0
Germany
State/province [58] 0 0
Essen
Country [59] 0 0
Germany
State/province [59] 0 0
München
Country [60] 0 0
Greece
State/province [60] 0 0
Attikí
Country [61] 0 0
Greece
State/province [61] 0 0
Kentrikí Makedonía
Country [62] 0 0
Greece
State/province [62] 0 0
Athens
Country [63] 0 0
Greece
State/province [63] 0 0
Ípeiros
Country [64] 0 0
Hungary
State/province [64] 0 0
Somogy
Country [65] 0 0
Hungary
State/province [65] 0 0
Budapest
Country [66] 0 0
Hungary
State/province [66] 0 0
Debrecen
Country [67] 0 0
Hungary
State/province [67] 0 0
Nyíregyháza
Country [68] 0 0
India
State/province [68] 0 0
Haryana
Country [69] 0 0
India
State/province [69] 0 0
Tamil NADU
Country [70] 0 0
India
State/province [70] 0 0
Uttarakhand
Country [71] 0 0
India
State/province [71] 0 0
WEST Bengal
Country [72] 0 0
India
State/province [72] 0 0
Delhi
Country [73] 0 0
Israel
State/province [73] 0 0
Hadarom
Country [74] 0 0
Israel
State/province [74] 0 0
Hamerkaz
Country [75] 0 0
Israel
State/province [75] 0 0
Hatsafon
Country [76] 0 0
Israel
State/province [76] 0 0
Tell Abib
Country [77] 0 0
Israel
State/province [77] 0 0
Yerushalayim
Country [78] 0 0
Israel
State/province [78] 0 0
Jerusalem
Country [79] 0 0
Italy
State/province [79] 0 0
Emilia-romagna
Country [80] 0 0
Italy
State/province [80] 0 0
Lazio
Country [81] 0 0
Italy
State/province [81] 0 0
Lombardia
Country [82] 0 0
Italy
State/province [82] 0 0
Sicilia
Country [83] 0 0
Italy
State/province [83] 0 0
Toscana
Country [84] 0 0
Italy
State/province [84] 0 0
Ancona
Country [85] 0 0
Italy
State/province [85] 0 0
Bologna
Country [86] 0 0
Italy
State/province [86] 0 0
Roma
Country [87] 0 0
Japan
State/province [87] 0 0
Aichi
Country [88] 0 0
Japan
State/province [88] 0 0
Gunma
Country [89] 0 0
Japan
State/province [89] 0 0
Hyogo
Country [90] 0 0
Japan
State/province [90] 0 0
Iwate
Country [91] 0 0
Japan
State/province [91] 0 0
Kyoto
Country [92] 0 0
Japan
State/province [92] 0 0
Miyagi
Country [93] 0 0
Japan
State/province [93] 0 0
Shizuoka
Country [94] 0 0
Japan
State/province [94] 0 0
Tokyo
Country [95] 0 0
Japan
State/province [95] 0 0
Kagoshima
Country [96] 0 0
Japan
State/province [96] 0 0
Kumamoto
Country [97] 0 0
Japan
State/province [97] 0 0
Okayama
Country [98] 0 0
Japan
State/province [98] 0 0
Osaka
Country [99] 0 0
Japan
State/province [99] 0 0
Yamagata
Country [100] 0 0
Korea, Republic of
State/province [100] 0 0
Incheon-gwangyeoksi [incheon]
Country [101] 0 0
Korea, Republic of
State/province [101] 0 0
Jeonranamdo
Country [102] 0 0
Korea, Republic of
State/province [102] 0 0
Kyonggi-do
Country [103] 0 0
Korea, Republic of
State/province [103] 0 0
Pusan-kwangyokshi
Country [104] 0 0
Korea, Republic of
State/province [104] 0 0
Seoul-teukbyeolsi [seoul]
Country [105] 0 0
Korea, Republic of
State/province [105] 0 0
Taegu-kwangyokshi
Country [106] 0 0
Netherlands
State/province [106] 0 0
Zuid-holland
Country [107] 0 0
Netherlands
State/province [107] 0 0
Maastricht
Country [108] 0 0
Netherlands
State/province [108] 0 0
Zwolle
Country [109] 0 0
Norway
State/province [109] 0 0
Hordaland
Country [110] 0 0
Norway
State/province [110] 0 0
Oslo
Country [111] 0 0
Norway
State/province [111] 0 0
Stavanger
Country [112] 0 0
Poland
State/province [112] 0 0
Wielkopolskie
Country [113] 0 0
Poland
State/province [113] 0 0
Gdansk
Country [114] 0 0
Poland
State/province [114] 0 0
Poznan
Country [115] 0 0
Poland
State/province [115] 0 0
Warszawa
Country [116] 0 0
Poland
State/province [116] 0 0
Wroclaw
Country [117] 0 0
Poland
State/province [117] 0 0
Slaskie
Country [118] 0 0
Spain
State/province [118] 0 0
A Coruna
Country [119] 0 0
Spain
State/province [119] 0 0
Barcelona [barcelona]
Country [120] 0 0
Spain
State/province [120] 0 0
Barcelona
Country [121] 0 0
Spain
State/province [121] 0 0
Castilla Y LEÓN
Country [122] 0 0
Spain
State/province [122] 0 0
Catalunya [cataluña]
Country [123] 0 0
Spain
State/province [123] 0 0
Madrid, Comunidad DE
Country [124] 0 0
Spain
State/province [124] 0 0
Madrid
Country [125] 0 0
Spain
State/province [125] 0 0
Navarra
Country [126] 0 0
Spain
State/province [126] 0 0
Gerona
Country [127] 0 0
Spain
State/province [127] 0 0
Salamanca
Country [128] 0 0
Spain
State/province [128] 0 0
València
Country [129] 0 0
Sweden
State/province [129] 0 0
Skåne LÄN [se-12]
Country [130] 0 0
Sweden
State/province [130] 0 0
Stockholms LÄN [se-01]
Country [131] 0 0
Sweden
State/province [131] 0 0
Västra Götalands LÄN [se-14]
Country [132] 0 0
Sweden
State/province [132] 0 0
Falun
Country [133] 0 0
Sweden
State/province [133] 0 0
Örebro LÄN [se-18]
Country [134] 0 0
Sweden
State/province [134] 0 0
Östergötlands LÄN [se-05]
Country [135] 0 0
Switzerland
State/province [135] 0 0
Zürich (DE)
Country [136] 0 0
Switzerland
State/province [136] 0 0
Baden
Country [137] 0 0
Switzerland
State/province [137] 0 0
Berne
Country [138] 0 0
Switzerland
State/province [138] 0 0
Winterthur
Country [139] 0 0
Taiwan
State/province [139] 0 0
Taichung
Country [140] 0 0
Taiwan
State/province [140] 0 0
Taipei
Country [141] 0 0
Taiwan
State/province [141] 0 0
Taoyuan
Country [142] 0 0
Turkey
State/province [142] 0 0
I?stanbul
Country [143] 0 0
Turkey
State/province [143] 0 0
I?zmir
Country [144] 0 0
Turkey
State/province [144] 0 0
Ankara
Country [145] 0 0
Turkey
State/province [145] 0 0
Antalya
Country [146] 0 0
Turkey
State/province [146] 0 0
Aydin
Country [147] 0 0
Turkey
State/province [147] 0 0
Kayseri
Country [148] 0 0
Turkey
State/province [148] 0 0
Kocaeli
Country [149] 0 0
United Kingdom
State/province [149] 0 0
Cambridgeshire
Country [150] 0 0
United Kingdom
State/province [150] 0 0
England
Country [151] 0 0
United Kingdom
State/province [151] 0 0
Wakefield
Country [152] 0 0
United Kingdom
State/province [152] 0 0
Belfast
Country [153] 0 0
United Kingdom
State/province [153] 0 0
Glasgow
Country [154] 0 0
United Kingdom
State/province [154] 0 0
Reading
Country [155] 0 0
United Kingdom
State/province [155] 0 0
Wolverhampton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Pfizer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the study, participants in the study will either receive elranatamab (arm A and C) as an injection under the skin at the study clinic or lenalidomide orally once daily at home (arm B). Participation in the study will be approximately five years
Trial website
https://clinicaltrials.gov/study/NCT05317416
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Pfizer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Country 0 0
Phone 0 0
1-800-718-1021
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05317416